ImmuPharma PLC (AIM:IMM) is set to participate in the BIO-Europe Spring gathering, which it describes as the "premier partnering event, designed to provide biotechnology companies".
Tim McCarthy, CEO, and Dr. Tim Franklin, COO, will represent the company at the gathering, which takes place in Barcelona from March 18-20.
"Following on from our recent announcements, including moving our lead asset P140 for SLE (Lupuzor) forward, with our appointed CRO, Simbec-Orion, in parallel with our CIDP program, we are delighted to have BIO-Europe as the next key platform in 2024 to present our unique portfolio to key industry and investment specialists," said McCarthy.
"Our focus will be to secure partnering opportunities across our programs including our P140 platform and our earlier stage but highly exciting anti-infective asset, BioAMB."